<DOC>
	<DOCNO>NCT00535860</DOCNO>
	<brief_summary>The purpose study assess clinical efficacy , safety , tolerability ViaDerm-shPTH [ 1-34 ] transdermal delivery comparison subcutaneous injection rhPTH [ 1-34 ] follow 3-month treatment postmenopausal woman Osteoporosis</brief_summary>
	<brief_title>Efficacy &amp; Safety ViaDerm-hPTH ( 1-34 ) Compared Forteo SC Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Main Inclusive Criteria : Postmenopausal woman age 55 85 year ( inclusive ) PosteriorAnterior lumbar vertebral and/or femoral neck BMD Tscore DXA â‰¤2.5 SD . Have normal serum PTH , thyroid stimulate hormone ( TSH ) ( patient treat thyroid hormone ) , prolactin value . Main Exclusive Criteria : Subjects clinical significant unstable medical surgical condition may preclude safe complete study participation Current diagnose disorder know affect bone metabolism include hyperthyroidism , hyperparathyroidism , osteomalacia , Paget 's disease Prior osteoporosis treatment fluoride strontium time ; IV treatment bisphosphonates past oral bisphosphonate 1 month past 24 month prior randomization . Any condition disease may interfere ability , evaluate DXA scan</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Transdermal</keyword>
	<keyword>hPTH ( 1-34 )</keyword>
</DOC>